Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)

Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)

The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.

The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Study Overview

• Status: Recruiting
• Conditions: Late Onset Sporadic Cerebellar Ataxia

Detailed Description

Progressive ataxia frequently starts in adults without a familial background. These patients may suffer from an acquired ataxia or a genetically determined ataxia despite negative family history. In the majority of them, however, a genetic or acquired cause of ataxia cannot be identified suggesting a sporadic degenerative ataxia. They can be subdivided into two groups. In one group, the underlying brain disease is multiple system atrophy (MSA), specifically MSA of cerebellar type (MSA-C). The characteristic clinical feature of MSA is the presence of severe autonomic failure defined by orthostatic hypotension or urinary incontinence. The second group is distinguished from MSA-C by the lasting absence of severe autonomic failure. These patients have been designated as sporadic adult onset ataxia of unknown aetiology (SAOA). In the first years after ataxia onset, a distinction between MSA-C and SAOA is often not possible.

There are only few studies comparing the phenotype of MSA-C and SAOA, and longitudinal studies focussing on the evolution of the phenotype of these disorders are completely lacking. In particular, the progression rate of SAOA compared to MSA-C has not been defined. In addition, it is unknown which factors predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.

To answer these questions, we plan to create a European registry of patients with sporadic degenerative ataxia of adult onset and to perform a natural history study. The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

• Study Type: Observational
• Enrollment (Anticipated): 300

Contacts and Locations

• Study Contact: Name: Ilaria Anna Giordano, MD; Phone Number: 0049 228 287 15750; Email: ilaria_anna.giordano@ukb.uni-bonn.de

Study Locations

• Austria
  • Innsbruck, Austria
    • Active, not recruiting
    • Department of Neurology, Medical University, Innsbruck
• Germany
  • Berlin, Germany
    • Recruiting
    • Universitatsmedizin Berlin Charite
    • Contact: Sarah Doss, MD; Email: sarah.doss@charite.de
  • Bonn, Germany, 53105
    • Recruiting
    • Department of Neurology, University of Bonn
    • Contact: Thomas Klockgether, Prof. Dr.; Email: thomas.klockgether@ukb.uni-bonn.de
    • Contact: Ilaria Giordano, MD; Email: ilaria_anna.giordano@ukb.uni-bonn.de
  • Essen, Germany
    • Recruiting
    • Department of Neurology, University Clinic Essen, University of Duisburg-Essen
    • Contact: Dagmar Timmann, MD; Email: dagmar.timmann-braun@uni-duisburg-essen.de
    • Contact: Johanna Reinold; Email: johanna.reinold@stud.uni-due.de
  • Frankfurt, Germany
    • Recruiting
    • Department of Neurology, University of Frankfurt
    • Contact: Jun-Suk Kang, MD; Email: jun-suk.kang@med.uni-frankfurt.de
  • Hamburg, Germany
    • Active, not recruiting
    • Hamburg UKE Abt. Neuropädiatrie
  • Magdeburg, Germany
    • Recruiting
    • Otto-von-Guericke Universität Magdeburg
    • Contact: Stefan Vielhaber, Prof. Dr.; Email: stefan.vielhaber@med.ovgu.de
  • München, Germany
    • Recruiting
    • Friedrich-Baur-Institut an der Neurologischen Klinik
    • Contact: Thomas Klopstock, Prof. Dr.; Email: thomas.klopstock@med.uni-muenchen.de
  • Rostock, Germany
    • Recruiting
    • Universitätsmedidzin Rostock - Klinik und Poliklinik für Neurologie
    • Contact: Cristoph Kamm, MD; Email: christoph.kamm@med.uni-rostock.de
  • Tübingen, Germany
    • Recruiting
    • Dept. of Neurodegenerative Diseases Tübingen
    • Contact: Ludger Schoels, Prof. Dr.; Email: ludger.schoels@dzne.de
• Italy
  • Naples, Italy
    • Recruiting
    • Department of Neuroscience, Federico II University Naples
    • Contact: Alessandro Filla, MD; Email: afilla@unina.it
    • Contact: Antonella Antenora; Email: antonella.antenora@virgilio.it
  • Rome, Italy
    • Active, not recruiting
    • Università Cattolica del Sacro Cuore
• Netherlands
  • Nijmegen, Netherlands
    • Active, not recruiting
    • Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour
• Norway
  • Oslo, Norway
    • Recruiting
    • Oslo University Hospital
    • Contact: Chantal M.E. Tallaksen, MD, PhD; Email: chantal.tallaksen@medisin.uio.no

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The study population consists of patients with adult onset degenerative ataxia, in which acquired and genetic causes of ataxia have been excluded.

Description

Inclusion Criteria:

• Progressive ataxia
• Disease onset after the age of 40 years
• Informative and negative family history (no similar disorders in first- and second-degree relatives; parents older than 50 years, or, if not alive, age at death of more than 50 years, no consanguinity of parents)

Exclusion Criteria:

• No established acquired cause of ataxia

Clinical exclusion criteria:

• No onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia or heat stroke;
• no chronic diarrhea;
• no unexplained visual loss;
• no alcohol abuse;
• no chronic intake of anticonvulsant drugs;
• no other toxic causes; no malignancies;
• no rapid progression (development of severe ataxia in less than 12 weeks);
• no insulin-dependent diabetes mellitus

Imaging exclusion criteria:

• No evidence of multiple sclerosis, ischemia, hemorrhage or tumor of the posterior fossa;
• absence of signal abnormalities on T2/FLAIR-images except abnormalities compatible with MSA

Laboratory exclusion criteria:

• Negative molecular genetic testing for FRDA (only required if there is no cerebellar atrophy on MRI, SCA1, SCA2, SCA3, SCA6, FMR1 premutation (only required if prominent tremor, cognitive impairment and signal abnormality on T2/FLAIR images in the middle cerebellar peduncle);
• antineuronal antibodies negative (only required, if disease duration less than 3 years);
• normal levels of vitamin B12;
• VDRL negative;
• normal thyreoid function

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
sporadic adult onset ataxia; SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
cerebellar multiple system atrophy; Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Scale for the assessment and rating of ataxia (SARA)	Both conditions (SAOA and MSAc) are part of neurodegenerative diseases, chronic progressive disorders. Their disease progression, can be measured using a validated ataxia scale, SARA. SARA was evaluated in two large validation trials performed by the EUROSCA clinical group and was found to be easy to use, reliable, and valid.	through study completion, an average of 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Inventory of non-ataxia signs (INAS)	The occurrence of accompanying non-ataxia symptoms is recorded using INAS.	through study completion, an average of 10 years
spinocerebellar ataxia functional index (SCAFI)	to assess the severity of ataxia in an objective way, three quantitative tests, 8m-walk, 9HPT (hole peg test) and PATA rate (timed speech task) are used.	through study completion, an average of 10 years
Unified Multiple System Atrophy Rating Scale (UMSARS)	UMSARS is a validated scale for multiple system atrophy used to assess additional symptoms typically occurring in MSA. The scale comprises the following components: Part I, historical, 12 items; Part II, motor examination, 14 items; Part III, autonomic examination; and Part IV, global disability scale.	through study completion, an average of 10 years
Questionnaire for Cerebellar Multisystem Atrophy diagnostic criteria	To distinguish between SAOA and MSAc adjusted criteria for multiple system atrophy of cerebellar type on the basis of consensus statement on the diagnostic criteria for MSAc are used (Second consensus statement on the diagnosis of multiple system atrophy: Neurology. 2008 Aug 26; 71(9): 670-676). Probable MSAc requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and cerebellar ataxia. Possible cerebellar MSA requires a sporadic, progressive adult-onset disease including cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality (Babinski sign with hyperreflexia, Stridor, Parkinsonism (bradykinesia and rigidity), Atrophy on MRI of putamen, middle cerebellar peduncle, or pons, Hypometabolism on FDG-PET in putamen, Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET. If both criteria are not met patient is classified as a SAOA.	through study completion, an average of 10 years
EQ-5D	Health related Quality of life is assessed using EQ-5D, a generic instrument that has been developed and validated by the EuroQuol Group (1990) and is available in validated translations for use as a questionnaire.	through study completion, an average of 10 years
PHQ-9	Assessment of depressive symptoms is done using a validated 9-item short form of the Patient Health Questionnaire (PHQ), a questionnaire that has been developed to screen for psychiatric co-morbidity in unselected populations	through study completion, an average of 10 years
Comparison of phenotype of cerebellar multiple system atrophy and sporadic adult onset ataxia of unknown etiology	classified as "SAOA" can convert into MSAc, that is why they are followed with yearly clinical assessments.	through study completion, an average of 10 years
RBDSQ	REM Behaviour Disorder Screening Questionnaire (RBDSQ)	through study completion, an average of 10 years

Collaborators and Investigators

• Sponsor: Ataxia Study Group
• Collaborators: German Center for Neurodegenerative Diseases (DZNE)
• Investigators: Principal Investigator: Thomas Klockgether, MD, Department of Neurology, Bonn, Germany

Publications and helpful links

General Publications

• Giordano I, Harmuth F, Jacobi H, Paap B, Vielhaber S, Machts J, Schols L, Synofzik M, Sturm M, Tallaksen C, Wedding IM, Boesch S, Eigentler A, van de Warrenburg B, van Gaalen J, Kamm C, Dudesek A, Kang JS, Timmann D, Silvestri G, Masciullo M, Klopstock T, Neuhofer C, Ganos C, Filla A, Bauer P, Tezenas du Montcel S, Klockgether T. Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology. 2017 Sep 5;89(10):1043-1049. doi: 10.1212/WNL.0000000000004311. Epub 2017 Aug 9.

Helpful Links

• Sportax Database

Study record dates

Study Major Dates

• Study Start: April 1, 2010
• Primary Completion (Anticipated): December 1, 2030
• Study Completion (Anticipated): December 1, 2030

Study Registration Dates

• First Submitted: January 28, 2016
• First Submitted That Met QC Criteria: March 2, 2016
• First Posted (Estimate): March 8, 2016

Study Record Updates

• Last Update Posted (Actual): June 29, 2017
• Last Update Submitted That Met QC Criteria: June 28, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: natural history; sporadic ataxia; MSAc; SAOA; multiple system atrophy of cerebellar type
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Dyskinesias; Cerebellar Diseases; Ataxia; Cerebellar Ataxia
• Other Study ID Numbers: SPORTAX 010/05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided